Barclays
PAVM icon

Barclays’s PAVmed PAVM Stock Holding History

Barclays’s Portfolio PAVM Stock Details PAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$446 Buy
+75
New +$531 ﹤0.01% 5024
2025
Q4 		– Sell
-2
Closed -$29 – 5560
2025
Q3 		$29 Buy
+2
New +$30 ﹤0.01% 5343
2023
Q1 		– Sell
-18
Closed -$3.84K – 5284
2022
Q4 		$3.84K Hold
18
– – ﹤0.01% 5036
2022
Q3 		$7K Hold
18
– – ﹤0.01% 4423
2022
Q2 		$7K Sell
18
-26
-59% -$12.6K ﹤0.01% 4721
2022
Q1 		$27K Sell
44
-170
-79% -$126K ﹤0.01% 4341
2021
Q4 		$237K Buy
214
+106
+98% +$230K ﹤0.01% 3503
2021
Q3 		$415K Buy
108
+61
+130% +$192K ﹤0.01% 3281
2021
Q2 		$137K Sell
47
-69
-59% -$163K ﹤0.01% 3717
2021
Q1 		$232K Buy
116
+89
+330% +$134K ﹤0.01% 3637
2020
Q4 		$26K Sell
27
-10
-27% -$8.55K ﹤0.01% 4625
2020
Q3 		$29K Sell
37
-7
-16% -$6.23K ﹤0.01% 4818
2020
Q2 		$42K Buy
+44
New +$44K ﹤0.01% 5003
2020
Q1 		– Hold
0
– – – 6381
2019
Q4 		– Hold
0
– – – 6692

Other funds holding PAVM

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Barclays's PAVM Position: Q2 2026 in Review

Barclays opened a new position in PAVmed (PAVM) in Q2 2026: 75 shares worth $446. The stake represents ﹤0.01% of the portfolio and ranks #5024 among its holdings. This is a return to the name: Barclays previously reported a position in PAVM as recently as Q3 2025.

Barclays first reported a position in PAVM in Q2 2020 and has held it in 13 quarters since. The position peaked at $415K in Q3 2021. 19 funds tracked by Wall St. Rank hold PAVM as of Q2 2026.

  • Barclays held 75 shares of PAVmed worth $446 as of Q2 2026.
  • PAVmed was a new Barclays position in Q2 2026.
  • PAVmed made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5024 holding.
  • Barclays first reported a position in PAVmed in Q2 2020 and has held it in 13 quarters since.
  • Barclays's PAVmed position peaked at $415K in Q3 2021.
  • 19 funds tracked by Wall St. Rank held PAVmed as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.